Selected statins produce rapid motor neuron loss in vivo

Beth B. Murinson, M.D., Ph.D., Norman J. Haughey, Ph.D., and Nicholas Maragakis, M.D., Ph.D.

Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, 21287

Corresponding Author:

Beth B. Murinson

Pathology 510, 600 North Wolfe Street

Baltimore, MD 21287

Email: bmurins1@jhmi.edu

Phone: 410 955-1423 Fax: 410 955-1961
ABSTRACT

Background: Hmg-CoA reductase inhibitors (statins) are widely used to prevent disease associated with vascular disease and hyperlipidemia. Although side effects are uncommon, clinical observations suggest statin exposure may exacerbate neuromuscular disease, especially amyotrophic lateral sclerosis. Although some have postulated class-effects, prior studies of hepatocytes and myocytes indicate that the statins may exhibit differential effects. Studies of neuronal cultures have been limited.

Methods: We examined the effects of statins on cultured neurons and Schwann cells. Cultured motoneurons were grown on transwell inserts and assessed for viability using immunochemical staining for SMI-32. Cultured cortical neurons and Schwann cells were assessed using dynamic viability markers.

Results: 7 days of exposure to fluvastatin depleted motoneurons in a dose-dependent manner with a $K_D$ of $< 2\mu M$. Profound neurite loss was observed after 4 days exposure in culture. Other statins were found to produce toxic effects at much higher concentrations. In contrast, no such toxicity was observed for cultured Schwann cells or cortical neurons.

Conclusions: It is known from pharmacokinetic studies that daily treatment of young adults with fluvastatin can produce serum levels in the single micromolar range. We conclude that specific mechanisms may explain neuromuscular disease worsening with statins and further study is needed.

Keywords: ALS, peripheral neuropathy, statins, toxicity, motoneuronopathy
BACKGROUND

Hmg-CoA reductase inhibitors (statins) are widely used for lowering cholesterol and the prevention of cardiovascular and cerebrovascular morbidity and mortality. Indeed, the use of statins has become more prevalent over time and selected populations, such as those discharged after hospital admission for stroke, have prevalence rates for statin prescription exceeding 80% [13].

Side effects of statin treatment are relatively uncommon. Rhabdomyolysis predominates as a side effect that may necessitate treatment cessation [6, 17]. Myalgias are more prevalent but often accepted as part of treatment [19]. Laboratory studies to investigate the mechanisms underlying muscle-related effects have shown that statins have negative effects on oxidative phosphorylation by muscle mitochondria [7]. The concentrations at which specific statins produce these effects varies widely and are generally considered to be outside the normal pharmacological dosing range exception for cerivistatin (now withdrawn from the market) and possibly fluvastatin [8]. More recent studies have shown that statins alter important second messenger events, e.g., the linkage of proteins to membrane via lipophilic isoprenyl molecules [7] the synthesis of which is directly inhibited by statins [12].

Clinical observations have suggested that statin exposure may unmask or accelerate the course of amyotrophic lateral sclerosis, (ALS) [20]. Substantial controversy has accompanied these observations and based on current studies, it is not clear whether there is a causal association or merely selection bias [4, 5]. Selection bias could arise if concerns about statins among ALS patients and their physicians lead to increased reporting of suspected effects. At present several questions remain unanswered. Among these is whether there is evidence that statins are directly toxic to motor neurons.
The culture of motoneurons in organotypic spinal cord cultures has been an instructive methodology to better understand the neurobiology of these cells [14] and has been used as a screening tool for the examination of potential candidate drugs for neuroprotective strategies in ALS [15]. Because of persistent concerns that statins may impact the course of ALS, we sought to examine the effects of statins on motoneurons in culture.
METHODS

Motoneuron cultures

All reagents were obtained from Sigma-Aldrich unless otherwise specified. Organotypic spinal cord cultures were prepared under sterile conditions from the lumbar spinal cords of 8-day old rat pups, using an approved protocol as previously described [14]. In brief, transverse 350 mm sections were prepared with a McIlwain tissue chopper. Sections were suspended in sterile Gey’s balanced salt solution (GIBCO) with glucose (6.4 mg/ml) and separated with gentle perturbation. Slices were transferred to Millipore trans-well inserts (30 mm Millicell-CM, 0.4mm pore membranes, Millipore, Bedford, MA). The transwell inserts were placed in 35 mm culture wells (Nalgene) containing 1 ml of growth medium and cultured at 37° C in a humidified 5%CO2/95% air incubator (Forma Scientific, Marietta OH). Growth medium consisted of Minimal essential medium-25 mM HEPES (50% vol), heat-inactivated horse serum (25% vol), and Hanks’ balanced salt solution (Life Technologies, Rockville) (25% vol), supplemented with D-glucose (25.6 mg/ml) and glutamine (2 mM), final pH 7.2. Cultures were fed twice weekly for 14 days prior to treatment. Treatments were carried out for 7 days with a change of medium after 4 days. Statins (simvastatin and fluvastatin from LKT Laboratories, St. Paul MN) were suspended in DMSO and diluted in growth medium before addition to culture. Control cultures contained DMSO at appropriate concentrations, in all cases less than 0.1%.

Cortical neuron cultures

Cortical neuron cultures were prepared as previously described from E18 rats [18]. Cultures were plated on poly-D-lysine coated plates at a density of 106 cells/ml, and established for 2 weeks prior to experimental assessment. Plating medium consisted of minimal essential medium containing 10% fetal bovine serum and antibiotics (1% of penicillin G 104 U/ml, streptomycin 10 mg/ml, amphotericin B 25
ug/ml). Three hours after plating, medium was changed to culture medium consisting of Neurobasal medium with 1x B-27 supplement (Life Technologies, Rockville, MD).

**Schwann cell cultures**

Schwann cell cultures were prepared as previously described from 1-day-old rat pups[1, 9]. Cultures were established for 2 weeks prior to experimental assessment. Culture medium consisted of Neurobasal medium (GIBCO) with 1% fetal bovine serum (HyClone, Logan UT) and glial cell line-derived neurotrophic factor (GDNF, ) at 10 ug/ml. Schwann cells were plated into 96-well plates, using brief trypsinization, 24 hours prior to experimental treatment.

**Immunochemistry and assessment of motoneuron cultures**

Cultures were fixed with 4% paraformaldehyde in 0.1M Sorenson's buffered solution (pH 7.4) for 30 minutes at room temperature. Immunochemistry was performed as previously described [11]. Slices were permeabilized with methanol, 20 minutes at 4°C. Rinsing with Tris-buffered saline preceded blocking with 10% normal goat serum, 1 hour at room temperature. Exposure to primary antibody (SMI-32, 1:8000) was at 4°C overnight. Signal amplification with Vectastain ABC (Vector, Burlingame, CA) preceded chromogenic development with diamino-benzidine (DAB) (Polyscience, Warrington, PA).

Motor neurons were specifically identified in the organotypic slices based on cell size, morphology, location in the ventral horn, and dense staining with SMI-32. Motor neuron counts were carried out in a blinded fashion on 12-16 explants for each condition and confirmed by a second investigator.

Additional cultures and immunochemical studies were performed on organotypic slice cultures with 4 days of treatment to ascertain whether neuritic degeneration preceded motoneuron degeneration. For this, slices were placed onto collagen-coated transwell inserts, known to promote the outgrowth of
neurites under appropriate conditions. Chromogenic development was performed using FITC-conjugated secondary antibody. Visualization of these slices was carried out using a Nikon Fluorescence microscope.

**Assessment of Cortical neuron cultures and Schwann cell cultures**

As a measure of statin cytotoxicity for cortical neurons and Schwann cells, ATP levels were measured as previously described [2] with minor modifications. Briefly, cells were plated into 96 well plates for 24 hours prior to treatment with statins, vehicle control solution or medium control solution. Following 24 hours of experimental treatment, measurement of ATP levels was performed using a commercially available luciferase-linked ATPase enzymatic assay (Vialight Plus, Cambrex).

**Statistical analysis**

The number of motor neurons in the slices of the experimental groups did not follow a normal distribution, for this reason median values are reported. For between group comparisons, data were transformed using a logarithmic function (log (N + 1)). Comparisons between groups were made on transformed data using a Chi-squared test with correction for multiple comparisons. 50% toxicity value for fluvastatin was estimated from data following a log-linear transformation of the data.
RESULTS AND DISCUSSION

Three commonly used statins were tested for toxicity to motoneurons in culture, these included fluvastatin, pravastatin, and simvastatin. As a group, the organotypic slice cultures retained normal conformational properties and were adherent to the membrane indicative of overall cellular integrity, consistent with observations that Schwann cell cultures demonstrate little or no toxicity of statins for glial cells. Motor neurons were strikingly depleted or absent from cultures exposed to fluvastatin, compare Figure 1A and 1B.

Quantitation of motoneurons showed that the median number per slice was 15 in the vehicle control group. The median number of motoneurons per slice was 0 in the 200 μM fluvastatin and simvastatin treatment groups, a significant decrease in motoneuron numbers (p < .001), Figure 1C. Treatment with 200 μM pravastatin yielded a median of 1 cell per slice, and also showed toxicity compared with control (p < .001). A limited dose-response curve for fluvastatin was obtained. Fluvastatin at 20 μM, was toxic for cultured motoneurons, median cells per slice was 0, (p < .001). Fluvastatin at 2 μM, was associated with partial toxicity, the median number of motoneurons of 5. This was significantly different from control, (p < .001) and from 20 μM and 200 μM fluvastatin, (p < .001). Replicate experiments showed analogous results.

Further assessment was made using cultures with only 4 days of statin exposure. Control organotypic slice cultures grown on collagen coated membranes exhibited robust ventral neurite outgrowth after 2.5 weeks in culture. By contrast, organotypic slices exposed to 200 μM fluvastatin for 96 hours demonstrated profound neuritic degeneration, Figure 2. Motoneuron staining, somewhat reduced, was still observable in these cultures.
In order to assess whether motor neurons were unusual in exhibiting cytotoxic responses to statin exposure, we assessed the effects of statin treatment on cortical neuron cultures and primary cultures of Schwann cells. No potentially relevant cytotoxic effects were observed for these cell types, Figure 3.

In this study, we demonstrate that in vitro exposure of motoneurons to selected statins, especially fluvastatin, resulted in marked cell loss. Shorter term exposures to fluvastatin resulted in neuritic degeneration. The results of this study provide evidence that specific pathophysiological mechanisms may underlie reports of neuromuscular disease exacerbation with statin exposure. The clinical implications of this study remain to be determined. There are multiple factors which might account for the differences between the clear in vitro toxicity reported here and the uncertainty surrounding observations of statin toxicity for motor systems in clinical settings.

Among the biological factors proposed to explain the wide clinical tolerability of statins are pharmacokinetics. Statins as a group are subject to high first-pass metabolism by the liver. This means that systemic levels are substantially below what might be predicted based on simple dilutional calculations. Statins do vary in the degree of first pass metabolism with the earlier statins being more extensively metabolized [8]. Interestingly the low first-pass metabolism of cerivastatin, initially hailed as a breakthrough, may have contributed to the high-rate of serious adverse events [17]. In addition, most statins are hydrophobic, with several newer statins being especially so. Pravastatin is uniquely hydrophilic and likely requires distinct consideration when considering systemic effects. In our study, there was the suggestion that pravastatin may be somewhat less toxic to cultured motoneurons, however further studies are needed. Finally, compartmental pharmacokinetics may limit the effects of statins on motoneurons. The extent to which specific statins attain significant concentrations in the
spinal fluid is not well understood. Studies in laboratory animals have indicated that the permeability of lipophilic statins, simvastatin and lovastatin into rat brain is orders of magnitude greater than that of pravastatin [16]. Thus, there are multiple pharmacokinetic reasons why statins may exhibit lower in vivo than in vitro toxicity. Nonetheless, pharmacokinetic data for fluvastatin, attained from clinical trials of the drug, suggest that a more cautious interpretation of our data may warranted.

Based on pharmacokinetics in man, it is estimated that the peak daily serum levels of fluvastatin after a 40 mg dose is in the low single micromolar range [3]. The results of the fluvastatin dose response studies we report here provide evidence that the drug concentration necessary to produce 50% toxicity for motoneurons in culture is less than 1 uM. Taken together, these data suggest that systemic levels of statins may approach levels that are toxic to motoneurons and that particular mechanisms must account for the relatively infrequent occurrence of clinically demonstrable toxicity. Perhaps sequestration of motoneurons in the spinal space is one such mechanism.

Based on these studies, it is not possible to specify a mechanism or mechanisms by which statins produce depletion of motoneurons in culture. Intriguingly, analogous to effects of statins in myotube cultures, it was observed that fluvastatin and simvastatin exhibit clearly evident toxicity, the effects of pravastatin were apparently more mild [8]. Mechanisms by which statins have produced undesirable effects in other systems should be explored. These include direct toxicity to mitochondrial membranes effects on products of mevalonate synthesis and signals mediated by the Liver X receptor complex [10].
CONCLUSIONS

In this study, we demonstrate that in vitro exposure of motoneurons to selected statins, especially fluvastatin, resulted in marked cell loss. Shorter term exposures to fluvastatin resulted in neuritic degeneration. The results of this study provide evidence that specific pathophysiological mechanisms may underlie reports of neuromuscular disease exacerbation with statin exposure.
ACKNOWLEDGEMENTS

The authors thank Carol Coccia for expert technical assistance. This work was supported by a Career Development Award from the National Institutes of Health (K08NS048146) to Dr. Murinson. Dr. Maragakis is supported in part by a grant from the Packard Center for ALS Research.
REFERENCES


FIGURE LEGENDS

Figure 1. Effect of statin exposure on motoneurons in organotypic spinal cord slices. Organotypic spinal cord slices were cultured for 3 weeks with exposure to vehicle control solution (A) or 20 uM fluvastatin (B) occurring during the last week of culture. Cultures were stained with SMI32 antibodies developed with DAB as described in the text, and motoneurons are immediately apparent in panel A, control cultures. A loss of motoneurons is evident following treatment with fluvastatin, shown in panel B. Bar equals 300 um. C) Quantitative assessment of statin effects on motoneurons in organotypic slice cultures. Number of motoneurons per slice for treatment with vehicle control solution or fluvastatin at 2 uM, 20 uM and 200 uM, pravastatin 200 uM and simvastatin 200 uM. All treatment groups demonstrated statistically significant decreases from control, after correction for multiple comparisons.

Figure 2. Effect of statin exposure on neurite outgrowth. Fluvastatin exposure for 96 hours resulted in a marked degeneration of neurites growing out from organotypic spinal cord cultures, when plated on collagen coated membranes. Cultures were stained with SMI32 antibodies developed with FITC-conjugated secondary antibody as described in the text. Vigorous outgrowth of ventral horn neurites is apparent in panel A, montage view (bar equals 1 mm) and panel B, detail view (bar equals 500 um). Neuritic degeneration is seen in panel C (bar equals 500 um).

Figure 3. Effect of statin exposure on primary Schwann cell and cortical neuron cultures. A) Statin treatment of Schwann cells for 24 hours did not result in significant toxicity except for very high concentrations of fluvastatin and simvastatin (500 uM). Three different statins are shown: fluvastatin, solid line; simvastatin, long dash; pravastatin, short dash. B) Statin treatment of cortical neurons for 24
hours did not result in significant toxicity. Three different statins are shown: fluvastatin, solid line; lovastatin, long dash; pravastatin, short dash. Data are shown normalized to vehicle control, error bars indicate standard deviation from the mean.